SMMT Summit Therapeutics PLC
Company Analysis
Latest News
🔴 Summit Therapeutics is trading 8.9% down today after wider Q2 loss and ivonescimab data update
Summit Therapeutics is trading at $13.65 (8.9% down) after reporting a wider second-quarter loss and providing updated Phase III HARMONi data for...
🔴 Summit Therapeutics is trading 4.6% down today after reporting a wider Q2 loss and no revenue
Summit Therapeutics is trading at $14.29 (-4.61%) in pre-market after its second-quarter earnings update revealed a wider loss and no revenue for the...
Summit Therapeutics Burns Through Cash Ahead of Its Make-or-Break FDA Decision — Can the Balance Sheet Last Long Enough?
Shares slid 6.5% to $14.01 in after-hours trading on July 23 after Summit Therapeutics reported a wider Q2 2026 net loss and reaffirmed elevated spending,...
Summit Therapeutics Establishes $380M At-The-Market Equity Offering Program
Summit Therapeutics has entered into a distribution agreement with J.P. Morgan Securities LLC to sell, from time to time, up to $380 million of its common...
🔴 Summit Therapeutics is trading 6.5% down today on a wider Q2 net loss and heavy R&D spending
Summit Therapeutics is trading 6.5% down at $14.01 after reporting a wider Q2 2026 net loss and reiterating plans for heavy R&D investment. • The company...
Summit Therapeutics reports a wider second quarter 2026 loss but strengthens its balance sheet ahead of a key ivonescimab PDUFA date.
Summit Therapeutics reported a GAAP net loss of $0.28 per share for the second quarter of 2026 with no revenue, as the company increased spending on clinical...
Summit Therapeutics Reports Favorable Ivonescimab Overall Survival Data from HARMONi Trial
Summit Therapeutics announced results from an updated overall survival (OS) analysis of its Phase III HARMONi clinical trial for ivonescimab. The trial is...
🟢 Summit Therapeutics is trading 6.6% up
Summit Therapeutics is trading at $15.60, up 6.6% from a comparison close of $14.63 during pre-market. This is a price-action follow-up, so a separate catalyst...
Summit Therapeutics PLC Q2 2026 Earnings Preview: What Analysts Expect on July 23, 2026
Analysts expect Summit Therapeutics to report a Q2 2026 loss of $0.26 per share on revenue of approximately $0.11 million, with the stock currently trading at...
🟢 Summit Therapeutics is trading 4.3% up today in a rebound from prior declines
Summit Therapeutics is trading at $14.08 (up 4.3%) as the stock rebounds from prior declines linked to ivonescimab trial and regulatory overhangs. • The move...
🔴 Summit Therapeutics is trading 10.2% down
Summit Therapeutics is trading at $13.54, down 10.2% from a comparison close of $15.07 during regular trading. This is a price-action follow-up, so a separate...
🔴 Summit Therapeutics is trading 4.1% down today on lingering trial and earnings concerns
Summit Therapeutics is trading at $14.45 (down 4.1%) as shares continue to drift lower following recent clinical and financial setbacks. • Investor sentiment...
🟢 SMMT extends move to 6.9% up
SMMT is trading at $15.37, up 6.9% versus the comparison close of $14.38 during regular trading. This is a price-movement alert; no separate company-specific...
🟢 SMMT is trading 4% up today after recent biotech volatility and prior trial news
SMMT is trading 4% up now at $14.96 after a stretch of volatile biotech trading and earlier news around its ivonescimab program. Recent weeks saw sharp moves...
Summit Therapeutics rated Buy, citing short squeeze potential and upcoming catalysts
Seeking Alpha initiated coverage on Summit Therapeutics with a cautious Buy rating. The analysis describes the company as a volatile, single-asset entity...
🟢 Summit Therapeutics PLC up 4.03% on recent $50M insider investment and withdrawn equity offering
Summit Therapeutics PLC is trading at $14.44 (+4.03%) today, fueled by a series of recent positive company-specific developments. • A director, Robert W....